HIV-1 DNA predicts disease progression and post-treatment virological control
| dc.contributor.author | Williams, James P. | |
| dc.contributor.author | Hurst, Jacob | |
| dc.contributor.author | Stöhr, Wolfgang | |
| dc.contributor.author | Robinson, Nicola | |
| dc.contributor.author | Brown, Helen | |
| dc.contributor.author | Fisher, Martin | |
| dc.contributor.author | Kinloch, Sabine | |
| dc.contributor.author | Cooper, David A. | |
| dc.contributor.author | Schechter, Mauro | |
| dc.contributor.author | Tambussi, Giuseppe | |
| dc.contributor.author | Fidler, Sarah | |
| dc.contributor.author | Carrington, Mary | |
| dc.contributor.author | Babiker, Abdel | |
| dc.contributor.author | Weber, Jonathan | |
| dc.contributor.author | Koelsch, Kersten K. | |
| dc.contributor.author | Kelleher, Anthony D. | |
| dc.contributor.author | Phillips, Rodney E. | |
| dc.contributor.author | Frater, John | |
| dc.contributor.author | Miró Meda, José M. (José María), 1956- | |
| dc.contributor.author | Gatell, José M. | |
| dc.contributor.author | SPARTAC Trial Investigators | |
| dc.date.accessioned | 2017-11-02T12:27:38Z | |
| dc.date.available | 2017-11-02T12:27:38Z | |
| dc.date.issued | 2014-09-12 | |
| dc.date.updated | 2017-11-02T12:27:38Z | |
| dc.description.abstract | In HIV-1 infection, a population of latently infected cells facilitates viral persistence despite antiretroviral therapy (ART). With the aim of identifying individuals in whom ART might induce a period of viraemic control on stopping therapy, we hypothesised that quantification of the pool of latently infected cells in primary HIV-1 infection (PHI) would predict clinical progression and viral replication following ART. We measured HIV-1 DNA in a highly characterised randomised population of individuals with PHI. We explored associations between HIV-1 DNA and immunological and virological markers of clinical progression, including viral rebound in those interrupting therapy. In multivariable analyses, HIV-1 DNA was more predictive of disease progression than plasma viral load and, at treatment interruption, predicted time to plasma virus rebound. HIV-1 DNA may help identify individuals who could safely interrupt ART in future HIV-1 eradication trials. | |
| dc.format.extent | 16 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 649160 | |
| dc.identifier.issn | 2050-084X | |
| dc.identifier.pmid | 25217531 | |
| dc.identifier.uri | https://hdl.handle.net/2445/117328 | |
| dc.language.iso | eng | |
| dc.publisher | eLife Sciences | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.7554/eLife.03821 | |
| dc.relation.ispartof | eLife, 2014, vol. 3, p. e03821 | |
| dc.relation.uri | https://doi.org/10.7554/eLife.03821 | |
| dc.rights | cc-by (c) Williams, James P. et al., 2014 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | |
| dc.source | Articles publicats en revistes (Medicina) | |
| dc.subject.classification | VIH (Virus) | |
| dc.subject.classification | Antiretrovirals | |
| dc.subject.classification | Malalties infeccioses | |
| dc.subject.classification | Assaigs clínics | |
| dc.subject.other | HIV (Viruses) | |
| dc.subject.other | Antiretroviral agents | |
| dc.subject.other | Communicable diseases | |
| dc.subject.other | Clinical trials | |
| dc.title | HIV-1 DNA predicts disease progression and post-treatment virological control | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1